Free Trial

Bicycle Therapeutics (NASDAQ:BCYC) Trading 6% Higher - Still a Buy?

Bicycle Therapeutics logo with Medical background
Remove Ads

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was up 6% during trading on Wednesday . The stock traded as high as $10.60 and last traded at $10.81. Approximately 4,893 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 293,263 shares. The stock had previously closed at $10.20.

Analyst Ratings Changes

Several equities research analysts have recently commented on BCYC shares. Needham & Company LLC reissued a "buy" rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research note on Tuesday. JMP Securities lowered their target price on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research note on Wednesday, December 18th. HC Wainwright reissued a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Stephens reissued an "equal weight" rating and issued a $15.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Finally, B. Riley lowered their target price on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.14.

Get Our Latest Research Report on BCYC

Bicycle Therapeutics Stock Performance

The firm has a market capitalization of $669.06 million, a P/E ratio of -2.95 and a beta of 1.12. The company has a 50-day moving average price of $12.44 and a 200-day moving average price of $18.55.

Remove Ads

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.10. The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company's revenue for the quarter was down 30.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.16) earnings per share. Equities analysts predict that Bicycle Therapeutics plc will post -3.06 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Travis Alvin Thompson sold 2,686 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the sale, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. The trade was a 7.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker purchased 500,000 shares of the business's stock in a transaction dated Monday, December 16th. The stock was purchased at an average price of $15.34 per share, for a total transaction of $7,670,000.00. Following the completion of the acquisition, the director now owns 9,995,274 shares of the company's stock, valued at approximately $153,327,503.16. This represents a 5.27 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 27,677 shares of company stock worth $392,413. Corporate insiders own 8.50% of the company's stock.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors have recently modified their holdings of BCYC. Principal Financial Group Inc. bought a new stake in shares of Bicycle Therapeutics in the third quarter valued at about $10,028,000. Assetmark Inc. acquired a new stake in shares of Bicycle Therapeutics in the third quarter valued at about $34,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Bicycle Therapeutics in the third quarter valued at about $257,000. L & S Advisors Inc increased its position in shares of Bicycle Therapeutics by 2.4% in the third quarter. L & S Advisors Inc now owns 59,735 shares of the company's stock valued at $1,352,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Westfield Capital Management Co. LP increased its position in shares of Bicycle Therapeutics by 21.5% in the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company's stock valued at $41,887,000 after acquiring an additional 327,089 shares during the last quarter. 86.15% of the stock is currently owned by institutional investors.

Bicycle Therapeutics Company Profile

(Get Free Report)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

Recommended Stories

Should You Invest $1,000 in Bicycle Therapeutics Right Now?

Before you consider Bicycle Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.

While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads